Yanhong Deng

Dr. Yanhong Deng


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2011 in Letters in Applied Microbiology
Verified
Journal Article
Open access
PDF file
JQJ. Qiu
J. Qiu
HLH. Li
H. Li
HMH. Meng
H. Meng
CHC. Hu
C. Hu
JLJ. Li
J. Li
XDXuming Deng
Xuming Deng
Aims: To investigate the influence of subinhibitory concentrations of luteolin on the production of α‐toxin in Staphylococcus aureus. Methods and Results: The minimal inhibitory concentrations (MICs) were determined using a broth microdilution method, and the MICs of luteolin against the tested Staph. aureus strains ranged from 16 to 64 μg ml−1. Haemolysis, Western blot and real‐time reverse transcription (RT)–PCR assays were used to evaluate the effect of luteolin on Staph. aureusα‐toxin secretion and on the level of gene expression, respectively. The data indicated that subinhibitory concentrations of luteolin dose dependently decreased the production of α‐toxin in both meticillin‐sensitive Staph. aureus (MSSA) and meticillin‐resistant Staph. aureus (MRSA). Furthermore, the transcriptional levels of agr (accessory gene regulator) in Staph. aureus were also inhibited by luteolin. Conclusions: Luteolin decreases the production and/or secretion of α‐toxin in Staph. aureus; the reduced production may be dependent, in part, upon the luteolin‐induced inhibition of the agr locus. Significance and Impact of the Study: The findings indicate that luteolin may be used as a basis for the development of antimicrobial agents aimed at bacterial virulence factors.

31 December 2022 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
XBXue Bai
Xue Bai
YSYong Shen
Yong Shen
TZTiehua Zhang
Tiehua Zhang
RMRizeng Meng
Rizeng Meng
YZYan Zhang
Yan Zhang
Na GuoNa Guo
Na Guo

24 May 2024 in Phytomedicine
Verified
Journal Article
Open access
NWNan Wang
Nan Wang
QSQiushuang Sheng
Qiushuang Sheng
HZHaoyu Zhu
Haoyu Zhu
JWJianfeng Wang
Jianfeng Wang
JQJiazhang Qiu
Jiazhang Qiu
LWLin Wang
Lin Wang
Polymyxin E is widely recognized as a last resort for treating multidrug-resistant gram-negative bacteria. Unfortunately, the effectiveness of polymyxin E is significantly reduced when treating life-threatening bacterial infections due to plasmid-mediated polymyxin E resistance. The synergistic effect of applying a polymyxin E adjuvant is a promising strategy for overcoming the growing threat of antibiotic-resistant pathogens. To evaluate the synergistic effect of fisetin and polymyxin E on S. typhimurium infections in vivo and further elucidate the underlying mechanism of this effect. The effect of combining fisetin and polymyxin E to treat mobilized colistin resistance-1-positive (MCR-1-positive) gram-negative bacteria in vitro was examined using various methods, such as checkerboard assays, growth curves and time‒kill curves. To elucidate the mechanism by which fisetin affects MCR-1, we employed ultraviolet (UV) absorption spectroscopy, thin layer chromatography (TLC), and western blot analysis to investigate its effect at the protein level. Subsequently, molecular dynamics simulations (MDS) and metabolomics analysis were utilized to determine the site of interaction between fisetin and MCR-1 as well as the potential pathways and mechanisms involved. A new nanoemulsion of fisetin was produced using high-pressure homogenization, and its stability was tested. Finally, two animal models of S. typhimurium HYM2 infection were established to evaluate the synergistic effect of polymyxin E and fisetin in vivo. Our study revealed that fisetin exhibited a synergistic effect when combined with polymyxin E against MCR-1-positive S. typhimurium. The TLC results demonstrated that fisetin could inhibit the phosphoethanolamine (PEA) transfer of the MCR-1 protein, thereby restoring the activity of polymyxin E in strains against MCR-1. The MDS analysis indicated robust and immediate binding between fisetin and the MCR-1 protein, with both hydrophobic and polar effects playing significant roles in determining the binding energy of the former. Metabolomic studies demonstrated that the addition of fisetin significantly modulated bacterial metabolites. Moreover, it effectively inhibited the activity of ABC transporters in bacteria, thereby mitigating bacterial drug resistance and enhancing the therapeutic efficacy of polymyxin E. Furthermore, in mouse and chick models of infection, intragastric administration of the fisetin nanoemulsion together with polymyxin E resulted in significant therapeutic benefits, including increased survival rates, reduced bacterial colonization, and decreased levels of inflammatory factors. Fisetin, an MCR-1 inhibitor and a promising synergistic partner of polymyxin E, has significant potential for clinical application in the treatment of S. typhimurium infections, particularly those resulting extensively from drug-resistant MCR-1-positive strains.

1 December 2021 in Life Sciences
Verified
Journal Article
Closed access
RDRunbao Du
Runbao Du
QLQianghua Lv
Qianghua Lv
WHWei Hu
Wei Hu
XHXiaoning Hou
Xiaoning Hou
YZYonglin Zhou
Yonglin Zhou
JWJianfeng Wang
Jianfeng Wang

31 October 2023 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
QSQiushuang Sheng
Qiushuang Sheng
NWNan Wang
Nan Wang
YZYonglin Zhou
Yonglin Zhou
XDXuming Deng
Xuming Deng
XHXiaoning Hou
Xiaoning Hou
YDYanhong Deng
Yanhong Deng
Background: Adjuvant addition of approved drugs or foodborne additives to colistin might be a cost-effective strategy to overcome the challenge of plasmid-mediated mobile colistin resistance gene emergence, which poses a threat in the clinic and in livestock caused by infections with Gram-negative bacteria, especially carbapenem-resistant Enterobacteriaceae. Methods: Chequerboard assay was applied to screen the colistin adjuvants from natural compounds. The killing–time curve, combined disc test and membrane permeation assay were conducted to identify the synergy efficacy of thymol and colistin in vitro. Thin-layer chromatography (TLC), LC-MS and fluorescence spectra were used to indicate the interaction of thymol and MCR-1. The potential binding sites were then investigated by molecular simulation dynamics. Finally, a thymol nanoemulsion was prepared with high-pressure homogenization as the clinical dosage form. Results: Thymol presented an excellent synergistic effect in vitro with colistin against Salmonella enterica serovar Typhimurium and Escherichia coli bacteria. Thymol addition, forming a complex with MCR-1, might interfere with the efficacy of MCR-1. Moreover, thymol strengthened colistin activity associated with potentiating membrane damage, destroying the biofilm and enhancing reactive oxygen species-mediated oxidative damage. Thymol nanoemulsion combined with colistin remarkably prevented the intestinal damage caused by S. Typhimurium infection, resulting in a survival rate higher than 60%. Conclusions: This study achieved a promising thymol oral formulation as colistin adjuvant to combat S. Typhimurium infection, which could be used to extend the lifespan of colistin in clinical veterinary medicine.

28 November 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
YSYong Shen
Yong Shen
XBXue Bai
Xue Bai
XZXiran Zhou
Xiran Zhou
JWJiaxi Wang
Jiaxi Wang
Na GuoNa Guo
Na Guo
YDYanhong Deng
Yanhong Deng
Starmerella bacillaris is often isolated from environments associated with grape and winemaking. S. bacillaris has many beneficial properties, including the ability to improve the flavor of wine, the production of beneficial metabolites, and the ability to biocontrol. S. bacillaris CC-PT4 (CGMCC No. 23573) was isolated from grape and can inhibit methicillin-resistant Staphylococcus aureus and adaptability to harsh environments. In this paper, the whole genome of S. bacillaris CC-PT4 was sequenced and bioinformatics analyses were performed. The S. bacillaris CC-PT4 genome was finally assembled into five scaffolds with a genome size of 9.45 Mb and a GC content of 39.5%. It was predicted that the strain contained 4150 protein-coding genes, of which two genes encoded killer toxin and one gene encoded lysostaphin. It also contains genes encoding F1F0-ATPases, Na(+)/H(+) antiporter, cation/H(+) antiporter, ATP-dependent bile acid permease, major facilitator superfamily (MFS) antiporters, and stress response protein, which help S. bacillaris CC-PT4 adapt to bile, acid, and other stressful environments. Proteins related to flocculation and adhesion have also been identified in the S. bacillaris CC-PT4 genome. Predicted by antiSMASH, two secondary metabolite biosynthesis gene clusters were found, and the synthesized metabolites may have antimicrobial effects. Furthermore, S. bacillaris CC-PT4 carried genes associated with pathogenicity and drug resistance. Overall, the whole genome sequencing and analysis of S. bacillaris CC-PT4 in this study provide valuable information for understanding the biological characteristics and further development of this strain.